| 高 洁,吕 敏,常相帝,王海婷,杨 敏.普罗布考联合阿魏酸哌嗪治疗早期糖尿病肾病的效果及对血清Cys-C、hs-CRP、TGF-β1、β2-MG水平的影响[J].,2018,(4):733-736 |
| 普罗布考联合阿魏酸哌嗪治疗早期糖尿病肾病的效果及对血清Cys-C、hs-CRP、TGF-β1、β2-MG水平的影响 |
| Clinical Effect of Probucol Combined with Piperazine Ferulate on Early Diabetic Nephropathy and Its Influence on Levels of Cys-C, hs-CRP, TGF-β1 and β2-MG |
| 投稿时间：2017-06-13 修订日期：2017-06-30 |
| DOI：10.13241/j.cnki.pmb.2018.04.029 |
| 中文关键词: 普罗布考 阿魏酸哌嗪 早期糖尿病肾病 临床疗效 |
| 英文关键词: Probucol Piperazine ferulate Early diabetic nephropathy Clinical effect |
| 基金项目:山东省自然科学基金项目(ZR2011HM083) |
|
| 摘要点击次数: 547 |
| 全文下载次数: 300 |
| 中文摘要: |
| 摘要 目的：探究阿魏酸哌嗪和普罗布考联合治疗早期糖尿病肾病(DN)的临床效果及对血清胱抑素C(Cys-C)、超敏C反应蛋白(hs-CRP)、转换生长因子-β1(TGF-β1)、β2-微球蛋白(β2-MG)水平的影响。方法：选取2016年2月~2017年2月我院收治的104例早期DN患者，采用随机数字表法均分为两组。对照组给予阿魏酸哌嗪治疗，观察组给予普罗布考和阿魏酸哌嗪联合治疗。比较两组治疗后临床疗效，治疗前后血清Cys-C、hs-CRP、TGF-β1水平、尿β2-MG水平的变化及不良反应的发生情况。结果：治疗12周后，观察组临床总有效率为92.3%，较对照组明显上升(P<0.05)。与治疗前对比，两组治疗12周后血清Cys-C、hs-CRP、TGF-β1、尿β2-MG水平均显著降低(P<0.01)，且观察组以上指标均显著低于对照组(P<0.01)。两组不良反应发生率相比差异无统计学意义(P>0.05)。结论：阿魏酸哌嗪和普罗布考联合治疗早期糖尿病肾病的临床疗效显著优于阿魏酸哌嗪单药治疗，且安全性较高，可能与其有效降低患者血清Cys-C、hs-CRP、TGF-β1和尿β2-MG水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of probucol combined with piperazine ferulate on early diabetic nephropathy (DN) and its influence on levels of serum cystatin-C (Cys-C), high sensitivity c-reactive protein(hs-CRP), transforming growth factor-β1 (TGF-β1) and urine β2-microglobulin (β2-MG). Methods: 104 cases of patients with early DN admitted in our hospital from February 2016 to February 2017 were selected and evenly divided into two groups on a random basis. The control group was treated with piperazine ferulate, while the observation group probucol in combination with piperazine ferulate. The clinical effect, changes of serum Cys-C, hs-CRP, TGF-β1 and urine β2-MG levels before and after treatment as well as the incidence of adverse reactions were compared between the two groups. Results: The overall effective rate of the observation group at 12 weeks after treatment was 92.3%, which was higher as compared with that of the control group (P<0.05). The levels of serum Cys-C, hs-CRP, TGF-β1 and urine β2-MG levels of both groups at 12 weeks after treatment were significantly decreased as compared with those before treatment, which were obviously lower in the observation group than those of te control group(P<0.01). No significant difference in the incidence of adverse reaction was found between the two groups(P>0.05). Conclusion: Probucol combined with piperazine ferulate was more effective than piperazine ferulate alone in treating early DN with high safety, which may be correlated with the decrease of the serum Cys-C, hs-CRP, TGF-β1 and urine β2-MG levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
